Novell, which has been at the centre of acquisition speculation for over a year, has prepared a poison pill defence to protect shareholders in the event of a hostile takeover bid. It has drawn up...
To continue reading this article...
Join CRN
- Enjoy full access to channelweb.co.uk - the UK’s top news source for the IT channel
- Gain the latest insights through market analysis and interviews with channel leaders
- Stay on top of key trends with the Insider weekly newsletter curated by CRN’s editor
- Be the first to hear about our industry leading events and awards programmes
Already a CRN member?
